Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3300+0.1600 (+13.68%)
At close: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Business Wire

    DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

    MINNEAPOLIS, September 14, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations. Ms. Daves, a recognized leader in managing global clinical studies, has significant experience in all phases of clinical development and will complement DiaMe

  • Business Wire

    DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference

    MINNEAPOLIS, September 06, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022. Management will conduct one-on-one meetings with investors during the conference.

  • Business Wire

    DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

    MINNEAPOLIS, August 10, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended June 30, 2022. DiaMedica will host a conference call on Thursday, August 11, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and second quarter financial results.

Advertisement
Advertisement